BF Biosciences Limited reported a net profit of Rs 184.88 million for the first quarter ended 30 September 2026
Filed as: Financial Results for the Quarter Ended 30-09-2026
Summary
BF Biosciences Limited reported a net profit of Rs 184.88 million for the first quarter ended 30 September 2026, with revenue reaching Rs 2.78 billion, reflecting a positive growth trend.
Read the original filingFigures in the filing
| Item | This period | Period before | Change |
|---|---|---|---|
| Revenue | PKR 2.78 B | PKR 2.43 B | +14.4% |
| Net Profit | PKR 184.88 M | PKR 159.52 M | +15.9% |
| Earnings Per Share | PKR 2.09 | PKR 1.81 | +15.5% |
| Gross Profit | PKR 1.28 B | PKR 1.04 B | +23.7% |
| Operating Profit | PKR 324.09 M | PKR 297.05 M | +9.1% |
Amounts are in Pakistani rupees as stated in the filing (M = million, B = billion).
What the filing says
- Revenue increased to Rs 2.78 billion, a growth of 14.44% from the prior period.
- Net profit rose to Rs 184.88 million, marking a 15.89% increase year-over-year.
- Earnings per share improved to Rs 2.09 from Rs 1.81, indicating enhanced profitability.
BF Biosciences Limited (BFBIO) on Nafa
Last price Rs 135.48 · Pharmaceuticals · You can own BFBIO shares from your phone.
More BFBIO announcements
- NoticeTransmission of Quarterly Financial Statements for the Period Ended 30-09-2026
- NoticeCertified true copy of the resolutions passed in the Annual General Meeting of the Company
- NoticeAnnual Progress Report for the Year Ended June 30, 2026
- NoticeBoard Meeting
- NoticeTransmission of Annual Financial Statements for the Year Ended 30-06-2026
- NoticeNotice of Annual General Meeting
Source: BF Biosciences Limited's filing with the Pakistan Stock Exchange. The summary and figures on this page are extracted from the filing by software and can contain errors; the filing itself is the record. This page describes the filing. It is not investment advice and Nafa does not recommend any stock. Investing in securities involves risk, including possible loss of principal.